Integrate drug cross-hypersensitive tools into your clinical workflow with Synbase
The Synbase platform enables the integration of allergies between drugs database into your electronic health record and the use of a complimentary web portal. #1 clinical decision support platform
Cross-hypersensitivity between drugs
Cross-hypersensitivities between drugs form a large group of preventable adverse drug reactions (ADRs), which can be prevented by clinical decision support.
Synbase platform prevents harm from cross-hypersensitivity reactions by
- Estimating the risk analyses at the single agent level
- Describing the frequency and clinical picture of the cross-reaction
- Providing clinical guidance to avoid future cross-hypersensitivity reactions
- Mapping drugs with local drug compendium
- Taking drug administration route into account
- Supporting search with local drug name
- Considering both prescription and over-the-counter (OTC) medication
- Available on a desktop, tablet, or mobile application.
Evidence-based cross-hypersensitivity database, covering prescription drugs, OTC drugs, and other substances
Clinical databaseAllergies between drugs database
Xreactbase provides evidence-based knowledge on cross-hypersensitivities of about 900 drugs that cause preventable drug harm.
Clinical experts have been producing all drug information according to standard operating procedures (SOPs), including published medical knowledge and the manufacturer-provided information approved by the European Medicines Agency (EMA) and/or The United States Food and Drug Administration (FDA) and data from national drug registers. All references are, whenever possible, linked to their source evidence.
Methodology of allergies between drugs database
High clinical usability – cross-hypersensitivity is classified according to clinical significance (A-D), resulting in a traffic light-like system:
|
A |
Evidence points to negligible risk of clinically relevant cross-hypersensitivity
|
|
B |
Information is limited or contradictory, and reliable risk assessment cannot be made |
|
C |
Evidence suggests that cross-hypersensitivity may exist, and drug administration should be done with caution or avoided if the previous hypersensitivity has been serious |
|
D |
Cross-hypersensitivity is common, and use should be avoided |
Regular updates for allergies between drugs database
Up-to-date drug data to provide medical advice – Xreactbase is developed and updated quarterly by Medbase Ltd (Finland).
